Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 325Uterine Cervical Neoplasms 131Endometrial Neoplasms 109Breast Neoplasms 99Carcinoma, Non-Small-Cell Lung 85Fallopian Tube Neoplasms 77Colorectal Neoplasms 74Carcinoma, Ovarian Epithelial 71Neoplasms 63Pancreatic Neoplasms 62Stomach Neoplasms 59Melanoma 57Neoplasm Metastasis 51Triple Negative Breast Neoplasms 49Squamous Cell Carcinoma of Head and Neck 43Prostatic Neoplasms 42Lung Neoplasms 41Esophageal Neoplasms 40Head and Neck Neoplasms 39Urinary Bladder Neoplasms 32Carcinoma, Renal Cell 31Sarcoma 29Recurrence 28Small Cell Lung Carcinoma 26Colonic Neoplasms 25Carcinoma, Hepatocellular 24Carcinoma, Transitional Cell 20Uterine Neoplasms 16Peritoneal Neoplasms 15Mesothelioma 15

Interventions

trifluridine tipiracil drug combination 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenomatous Polyposis Coli × Gynecologic × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡